Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Advanced Neural Dynamics","sponsor":"Neuropathix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuropathix, Inc. Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Advanced Neural Dynamics

    Menu

    Advanced Neural Dynamics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Advanced Neural Dynamics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neuropathix, Inc. Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate

              Details:

              Neuropathix has acquired novel hydroxylated sulfamides from Advanced Neural Dynamics and Fox Chase Chemical Diversity Center. These acquisitions provide Neuropathix another exciting avenue for strong clinical pipelines.

              Lead Product(s): Hydroxylated Sulfamides derivatives

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Neuropathix

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition December 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY